







an Open Access Journal by MDPI

Cancer Chemoradiotherapy

Guest Editor:

Dr. Chiwen Luo

Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan

Deadline for manuscript submissions:

20 July 2024

Message from the Guest Editor

Chemoradiotherapy is the combination of both chemotherapy and radiotherapy as an anticancer strategy. The goal of chemoradiotherapy is to achieve a synergistic anticancer effect from the combination of both treatment Chemoradiotherapy modalities. has become established treatment for a diverse range of locally advanced solid tumors. It offers notable survival benefits and local disease control without significant long-term toxicity. However, the efficiency and outcome of the treatment require the optimization/fractionation of the radiation/chemotherapy dose and administration timing. This Special Issue calls for the clarification and better understanding of the chemoradiotherapy concept and its application in clinical settings.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us